Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Lincomycin
Accession Number
DB01627
Type
Small Molecule
Groups
Approved, Vet approved
Description

An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.

Structure
Thumb
Synonyms
  • Cillimycin
  • LCM
  • Lincomicina
  • Lincomycin
  • Lincomycine
  • Lincomycinum
External IDs
U-10,149 / U-10149
Product Ingredients
IngredientUNIICASInChI Key
Lincomycin hydrochlorideGCW8Y9936L859-18-7POUMFISTNHIPTI-BOMBIWCESA-N
Lincomycin hydrochloride monohydrateM6T05Z2B687179-49-9LFZGYTBWUHCAKF-DCNJEFSFSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LincocinSolution300 mgIntramuscular; IntravenousPfizer Canada Ulc1964-12-312016-05-06Canada
LincocinCapsule500 mgOralPfizer Canada Ulc1964-12-312006-08-02Canada
LincocinInjection, solution300 mg/1mLIntramuscular; Intravenous; SubconjunctivalPharmacia and Upjohn Company LLC1964-12-29Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LincomycinInjection, solution300 mg/1mLIntramuscular; Intravenous; SubconjunctivalA-S Medication Solutions2015-07-05Not applicableUs
LincomycinInjection, solution300 mg/1mLIntramuscular; Intravenous; SubconjunctivalX-GEN Pharmaceuticals, Inc.2015-07-05Not applicableUs
LincomycinInjection, solution300 mg/1mLIntramuscular; Intravenous; SubconjunctivalX-GEN Pharmaceuticals, Inc.2015-07-05Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Lincobect / Lincorex
Categories
UNII
BOD072YW0F
CAS number
154-21-2
Weight
Average: 406.54
Monoisotopic: 406.213757997
Chemical Formula
C18H34N2O6S
InChI Key
OJMMVQQUTAEWLP-KIDUDLJLSA-N
InChI
InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1
IUPAC Name
(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
SMILES
[H][C@]1(C[C@@H](CCC)CN1C)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O

Pharmacology

Indication

Lincomycin is an antibiotic used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.

Associated Conditions
Pharmacodynamics

Lincomycin is a lincosamide antibiotic that produced by Streptomyces lincolnensis. Lincomycin has been shown to be active in vitro against the following microorganisms: Aerobic gram-positive cocci: Streptococcus pyogenes and Viridans group streptococci; Aerobic gram-positive bacilli: Corynebacterium diphtheriae; Anaerobic gram-positive non-sporeforming bacilli: Propionibacterium acnes; Anaerobic gram-positive sporeforming bacilli: Clostridium tetani and Clostridium perfringens.

Mechanism of action

Lincomycin inhibits protein synthesis in susceptible bacteria by binding to the 50 S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible organisms.

TargetActionsOrganism
A50S ribosomal protein L10
inhibitor
Shigella flexneri
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Rapidly absorbed from the gastrointestinal tract following oral administration. Approximately 20 to 30% absorbed orally in fasting state; absorption decreased when taken with food.

Volume of distribution
Not Available
Protein binding

Protein binding decreases with increased plasma concentrations. Range, 28 to 86% (average, 70 to 75%). Albumin is not thought to be the primary binding component.

Metabolism

Presumed hepatic, however metabolites have not been fully characterized.

Route of elimination

Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 3 percent). Biliary excretion is also an important route of excretion.

Half life

The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life may be prolonged in patients with severe impairment of renal function. Half life may be extended up to 2-fold in patients with hepatic impairment.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Lincomycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Lincomycin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Lincomycin is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Lincomycin is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Lincomycin is combined with Acenocoumarol.
AcepromazineAcepromazine may increase the neurotoxic activities of Lincomycin.
AceprometazineAceprometazine may increase the neurotoxic activities of Lincomycin.
AcetophenazineAcetophenazine may increase the neurotoxic activities of Lincomycin.
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Lincomycin.
AlimemazineAlimemazine may increase the neurotoxic activities of Lincomycin.
AmineptineLincomycin may increase the neurotoxic activities of Amineptine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take on an empty stomach, food decreases absorption.

References

Synthesis Reference

Alexander D. Argoudelis, David W. Stroman, "Process of producing lincomycin nucleotides." U.S. Patent US4464466, issued June, 1972.

US4464466
General References
Not Available
External Links
KEGG Drug
D00223
KEGG Compound
C06812
PubChem Compound
3000540
PubChem Substance
46506668
ChemSpider
2272112
BindingDB
50335522
ChEBI
6472
ChEMBL
CHEMBL1447
Therapeutic Targets Database
DAP000839
PharmGKB
PA164749212
HET
3QB
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lincomycin
ATC Codes
J01FF02 — Lincomycin
PDB Entries
4wh5 / 5hkv

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedNot AvailableBacterial Infections1
4Active Not RecruitingTreatmentCellulitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Bimeda Inc.
  • Carlisle Laboratories Inc.
  • Clint Pharmaceutical Inc.
  • Dispensing Solutions
  • Keene Pharmaceuticals Inc.
  • Llorens Pharmaceutical
  • Martin Surgical Supply
  • Medisca Inc.
  • Nord Ost Corp.
  • Pharmacia Inc.
  • Preferred Pharmaceuticals Inc.
  • Raz Co. Inc.
Dosage forms
FormRouteStrength
CapsuleOral500 mg
Injection, solutionIntramuscular; Intravenous; Subconjunctival300 mg/1mL
SolutionIntramuscular; Intravenous300 mg
Prices
Unit descriptionCostUnit
Lincocin 300 mg/ml vial7.79USD ml
Lincomycin hcl powder3.29USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP0.56HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility29.3 mg/mLALOGPS
logP0.5ALOGPS
logP-0.32ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)12.37ChemAxon
pKa (Strongest Basic)7.97ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area122.49 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity102.67 m3·mol-1ChemAxon
Polarizability43.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5937
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7945
P-glycoprotein inhibitor INon-inhibitor0.6755
P-glycoprotein inhibitor IINon-inhibitor0.5633
Renal organic cation transporterNon-inhibitor0.8868
CYP450 2C9 substrateNon-substrate0.8417
CYP450 2D6 substrateNon-substrate0.8837
CYP450 3A4 substrateSubstrate0.6389
CYP450 1A2 substrateNon-inhibitor0.9222
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9269
CYP450 2C19 inhibitorNon-inhibitor0.9203
CYP450 3A4 inhibitorNon-inhibitor0.9342
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9563
Ames testNon AMES toxic0.7696
CarcinogenicityNon-carcinogens0.9482
BiodegradationNot ready biodegradable0.9622
Rat acute toxicity2.5777 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9847
hERG inhibition (predictor II)Non-inhibitor0.7163
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.07 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000j-0900000000-1f46f29c3d5dbc6c25f6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0901000000-3fc103447a71fd95cedd
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-016r-0895000000-4b0507fffd39d9fc075f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00mk-0952000000-ca2f735ea2244e1cb32e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0901200000-cc68fda14967bfcd7357
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-70466cfb7e0692d073a0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-b712dc39bbf605193fb4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0109000000-cdbfa33f16a571dd85ee
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0209000000-8ec5c595eb6720c93c13

Taxonomy

Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
Alpha amino acid amides / Thioglycosides / Pyrrolidinecarboxamides / Monosaccharides / N-alkylpyrrolidines / Oxanes / Monothioacetals / Trialkylamines / Secondary carboxylic acid amides / Secondary alcohols
show 8 more
Substituents
Proline or derivatives / Alpha-amino acid amide / Glycosyl compound / S-glycosyl compound / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide / Monosaccharide / Oxane / N-alkylpyrrolidine / Monothioacetal
show 23 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid amide, pyrrolidinecarboxamide, L-proline derivative, carbohydrate-containing antibiotic, S-glycosyl compound (CHEBI:6472)

Targets

Kind
Protein
Organism
Shigella flexneri
Pharmacological action
Yes
Actions
Inhibitor
General Function
Structural constituent of ribosome
Specific Function
Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA (By similarity).Forms part of the ribosomal stalk, playing a cent...
Gene Name
rplJ
Uniprot ID
P0A7J6
Uniprot Name
50S ribosomal protein L10
Molecular Weight
17711.38 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Odom OW, Hardesty B: Use of 50 S-binding antibiotics to characterize the ribosomal site to which peptidyl-tRNA is bound. J Biol Chem. 1992 Sep 25;267(27):19117-22. [PubMed:1527036]
  3. Champney WS, Tober CL: Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35. [PubMed:10856379]

Drug created on August 29, 2007 15:12 / Updated on November 05, 2019 16:59